Question 1

What is Daratumumab?

Accepted Answer

Daratumumab is a type of targeted therapy known as a monoclonal antibody. It works by attaching to a specific protein called CD38, which is found on the surface of certain blood cells and cancer cells.

Once attached, the medication helps the body's immune system recognize and attack these cells. This process helps slow or stop the growth of cancer cells in the body.

Question 2

What is Daratumumab used for?

Accepted Answer

Daratumumab is used to treat multiple myeloma and light chain amyloidosis.

Question 3

How does Daratumumab work?

Accepted Answer

Mechanism of Action

Daratumumab belongs to a class of medications known as monoclonal antibodies. These are laboratory-made proteins designed to target specific markers on cells in the body.

This medication works by attaching to a protein called CD38. This protein is found in high amounts on the surface of multiple myeloma cells and certain other abnormal cells, such as those involved in light chain (AL) amyloidosis.

Once daratumumab binds to the CD38 protein, it helps fight the disease through several mechanisms:

Immune System Activation: It acts as a signal that helps the body's own immune system recognize, target, and kill the cancer cells.

Direct Cell Death: The binding process can trigger the cancer cells to self-destruct or break down directly.

Growth Inhibition: It may interfere with the signals that cancer cells need to grow and survive.

By focusing on cells that express CD38, the treatment aims to reduce the number of abnormal cells while minimizing the impact on many types of healthy cells.

Question 4

What are the brand names for Daratumumab?

Accepted Answer

Daratumumab is sold under the brand name Darzalex .

Question 5

What are the active ingredients in Daratumumab?

Accepted Answer

The active ingredient in Daratumumab is daratumumab .

Question 6

What are the side effects of Daratumumab?

Accepted Answer

Common side effects of Daratumumab may include:

infusion reactions

fatigue

nausea

and others

Always consult with a healthcare professional about potential side effects.

Question 7

What drug class is Daratumumab?

Accepted Answer

Daratumumab belongs to the CD38-directed monoclonal antibody drug class.

Question 8

What is the dosage of Daratumumab and how do I take it?

Accepted Answer

Administration

Daratumumab is given by a healthcare professional in a hospital or clinic setting. It is available in two forms:

Intravenous infusion: The medication is delivered slowly into a vein through a needle or catheter. The first infusion usually takes several hours, while subsequent infusions may be shorter.

Subcutaneous injection: The medication is injected under the skin, usually in the stomach area, over a few minutes.

Dosing Schedule

The treatment schedule for daratumumab is divided into phases. It is typically given once a week for several weeks, then every two weeks, and eventually once every four weeks. A healthcare provider will determine the exact schedule based on how the patient responds to the treatment and whether it is being used in combination with other medications.

Pre-treatment and Post-treatment Medications

To reduce the risk of infusion or injection reactions, healthcare providers will prescribe other medications to be taken before and after each dose. These may include:

Corticosteroids

Antihistamines

Fever reducers

Missed Doses

If an appointment for treatment is missed, the healthcare provider should be contacted immediately to reschedule. It is important to stay on the prescribed schedule to ensure the medication is effective.

Question 9

Is Daratumumab safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

Daratumumab may cause harm to an unborn baby. This medication is a monoclonal antibody that can cross the placenta and potentially affect the immune system of the fetus. It is important to notify a healthcare provider if you are pregnant or planning to become pregnant before starting this treatment.

Contraception

Individuals of reproductive potential are advised to use effective birth control during treatment and for at least 3 months after the last dose of daratumumab. Consult with a healthcare professional to determine the most appropriate method of contraception.

Breastfeeding

It is not known if daratumumab is present in human breast milk or if it could affect a nursing infant. Due to the potential for serious side effects, breastfeeding is typically not recommended during treatment and for 3 months following the final dose. Patients should discuss feeding options with their healthcare team.

Question 10

What forms and strengths does Daratumumab come in?

Accepted Answer

Daratumumab is available in two primary formulations for administration by a healthcare professional:

Solution for Intravenous Infusion: This formulation is provided in single-dose vials and must be diluted before being administered into a vein.

Solution for Subcutaneous Injection: This formulation, which includes hyaluronidase-fihj, is provided in single-dose vials for injection under the skin.

Question 11

What is the FDA approval status of Daratumumab?

Accepted Answer

FDA Approval and Indications

Daratumumab received its initial approval from the U.S. Food and Drug Administration (FDA) in 2015. It is primarily indicated for the treatment of adult patients with multiple myeloma, a cancer of the plasma cells. The medication is approved for use at various stages of the disease, including as a first-line treatment for newly diagnosed patients and as a therapy for those whose cancer has returned or failed to respond to previous treatments.

The FDA has also approved a subcutaneous formulation, which combines daratumumab with hyaluronidase-fihj, for the treatment of adults with light chain (AL) amyloidosis in combination with other specific chemotherapy regimens.

Recent Regulatory Updates

In 2024, the FDA approved the subcutaneous formulation of daratumumab in combination with bortezomib, lenalidomide, and dexamethasone for newly diagnosed patients with multiple myeloma who are eligible for an autologous stem cell transplant.

The medication is also approved for the treatment of patients with high-risk smoldering multiple myeloma.

Safety and Monitoring Requirements

While daratumumab does not carry a Boxed Warning, the FDA requires specific safety protocols during its use. Healthcare providers must monitor patients for infusion-related or injection-related reactions, which are common and may require pre-treatment with corticosteroids or antihistamines.

Regulatory labeling also includes requirements for hepatitis B virus screening before starting the medication, as daratumumab can cause the virus to become active again in carriers. Additionally, because the drug can interfere with blood compatibility testing (cross-matching), patients are advised to carry an identification card informing healthcare providers of their treatment if they require a blood transfusion.

Question 12

What should I know about Daratumumab and cost?

Accepted Answer

Factors Influencing Cost

Several factors determine the total cost of treatment with daratumumab, including:

Dosage and Frequency: The amount of medication needed and how often it is administered (which typically changes throughout the course of treatment) impact the overall price.

Administration Method: Daratumumab is available as an intravenous infusion or a subcutaneous injection. The costs for the medication and the professional services required to administer it may differ.

Treatment Setting: Receiving the medication in a hospital outpatient department may result in different costs compared to a private clinic or specialized infusion center.

Insurance and Financial Assistance

Because daratumumab is a specialty biologic medication, most insurance providers, including Medicare and private plans, require prior authorization before approving coverage. Patients may still be responsible for out-of-pocket costs, such as deductibles, copayments, or coinsurance.

Financial assistance may be available for eligible patients through various channels:

Manufacturer-sponsored patient assistance programs for those who are uninsured or underinsured.

Copay savings cards for individuals with commercial insurance.

Support from non-profit organizations and foundations that provide grants for specific medical conditions.

Patients should consult with their healthcare provider's billing office or their insurance company to obtain a precise estimate of their expected out-of-pocket expenses.

Daratumumab

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Brand Names

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Additional Resources

Support & Help Resources

Found an Error?